PD-L1 expression in head and neck cancer tissue specimens decreases with time

被引:15
|
作者
Karpathiou, Georgia [1 ]
Vincent, Maureen [1 ]
Dumollard, Jean Marc [1 ]
Mobarki, Mousa [2 ]
Peoc'h, Michel [1 ]
机构
[1] Univ Hosp St Etienne, Pathol Dept, F-42055 St Etienne 2, France
[2] Jazan Univ, Fac Med, Pathol Dept, Jazan, Saudi Arabia
关键词
Pre-analytical; Tissue quality; Tissue age; Laryngeal; Pharyngeal; Squamous cell carcinoma; Immunotherapy;
D O I
10.1016/j.prp.2022.154042
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: PD-L1 immunohistochemical expression is used as an important theranostic marker in various malignancies, including head and neck squamous cell carcinoma (HNSCC) where the combined positive score (CPS) guides treatment decisions. Despite indirect evidence that there is loss of antigenicity for archived tissues, there is no direct comparison between PD-L1 expression of the same tissue upon arrival and after its storage.Material and Methods: We compared the immunohistochemical expression of PD-L1 (22C3) in 106 HNSCC upon their arrival and after their storage (interval ranging from 20 to 48 months, mean 30.8 months). The evaluation was performed by two different pathologists' groups.Results: We found a statistically significant decrease in the PD-L1 tumor proportional score (TPS), immune cells expression (IC) and CPS between the initial and the newly stained slides.Conclusion: This is the first study comparing PD-L1 expression between a tissue and "himself" later in time, highlighting an important decrease in expression by tumor and immune cells, and suggesting that an immediate rather than a retrospective assay of PD-L1 expression should be preferable in the routine practice.Data Availability: Data are available upon reasonable request.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
    Qiao, Xin-wei
    Jiang, Jian
    Pang, Xin
    Huang, Mei-chang
    Tang, Ya-jie
    Liang, Xin-hua
    Tang, Ya-ling
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [2] The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment
    Pai, Sara I.
    Zandberg, Dan P.
    Strome, Scott E.
    ORAL ONCOLOGY, 2016, 61 : 152 - 158
  • [3] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
    Jiang, Siqing
    Li, Xin
    Huang, Lihua
    Xu, Zhensheng
    Lin, Jinguan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] PD-L1 expression in recurrent head and neck squamous cell carcinoma
    Delafoy, Alice
    Uguen, Arnaud
    Lemasson, Gilles
    Conan-Charlet, Virginie
    Pradier, Olivier
    Lucia, Francois
    Schick, Ulrike
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2022, 279 (01) : 343 - 351
  • [5] HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings
    Boschert, Verena
    Teusch, Jonas
    Aljasem, Anwar
    Schmucker, Philipp
    Klenk, Nicola
    Straub, Anton
    Bittrich, Max
    Seher, Axel
    Linz, Christian
    Mueller-Richter, Urs D. A.
    Hartmann, Stefan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 14
  • [6] Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer
    Sener, Görkem Yazici
    Sutcuoglu, Osman
    Ogut, Betül
    Guven, Deniz Can
    Kavuncuoglu, Altan
    Ozdemir, Nuriye
    Ozet, Ahmet
    Aksoy, Sercan
    Tezel, Yesim Gaye Güler
    Akyurek, Nalan
    Yazici, Ozan
    STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 (08) : 761 - 772
  • [7] PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection
    Lyu, Xintong
    Zhang, Miao
    Li, Guang
    Jiang, Yuanjun
    Qiao, Qiao
    JOURNAL OF CANCER, 2019, 10 (04): : 937 - 948
  • [8] Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
    Ran, Xiongwen
    Yang, Kai
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2007 - 2014
  • [9] Comparison of PD-L1 assays in head and neck carcinoma
    Jeong, Ji-seon
    Jo, Uiree
    Choi, Gyuheon
    Song, Halim
    Cho, Kyung-ja
    PATHOLOGY, 2024, 56 (07) : 969 - 981
  • [10] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272